KRT88P and lymphoma: Therefore, we detected the HBV DNA loads in both HBsAg positive, anti-HBc positive (HBsAg+) lymphoma patients and HBsAg negative, anti-HBc positive (HBsAg−/anti-HBc+) lymphoma patients during the whole chemotherapy cycle (C) and at a 24-month follow-up (M), in order to find out the changes and characteristics of the HBV DNA loads in lymphoma patients during chemotherapy and the follow-up.